Ambagon Therapeutics
Luc Brunsveld, Ph.D., performed his Ph.D. research at TU/e and the University of Illinois at Urbana-Champaign (USA) in the field of supramolecular chemistry, under the supervision of Prof. E.W. (Bert) Meijer (2001, cum laude). He was a postdoctoral fellow with Prof. Herbert Waldmann at the Max-Planck Institute of Molecular Physiology (Dortmund, Germany) working on protein semi-synthesis (2001-2002), followed by two years as a group leader in medicinal chemistry at Organon (Oss, the Netherlands, now Merck). In 2005, he started a research group at MPI in Dortmund working on supramolecular chemical biology, and subsequently also became group leader at the Chemical Genomics Centre of the Max Planck Society, working on Nuclear Receptor protein interactions. In 2008, he moved to TU/e where he was appointed Full Professor of Chemical Biology in the Department of Biomedical Engineering. Luc awards include the NVBMB Award of the Dutch Society for Biochemistry and Molecular Biology in 2010, the Gold Medal of the Royal Netherlands Chemical Society KNCV in 2013, and the NWO Vici grant (2015).
This person is not in the org chart
This person is not in any offices
Ambagon Therapeutics
Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins.